Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies. [electronic resource]
- Clinical cancer research : an official journal of the American Association for Cancer Research 03 2018
- 1103-1113 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
1557-3265
10.1158/1078-0432.CCR-17-2218 doi
Aminopyridines--pharmacology Animals Antineoplastic Combined Chemotherapy Protocols--pharmacology B-Lymphocytes--metabolism Benzamides--pharmacology Catalytic Domain--drug effects Cell Line, Tumor Cell Survival--drug effects Class I Phosphatidylinositol 3-Kinases--antagonists & inhibitors Cyclic Nucleotide Phosphodiesterases, Type 4--genetics Cyclopropanes--pharmacology Drug Repositioning Drug Synergism Humans Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy Lymphoma, Large B-Cell, Diffuse--drug therapy Mice Mice, Nude Phosphodiesterase 4 Inhibitors--pharmacology Protein Kinase Inhibitors--pharmacology Purines--pharmacology Quinazolinones--pharmacology Receptors, Antigen, B-Cell--metabolism Signal Transduction--drug effects Syk Kinase--metabolism Xenograft Model Antitumor Assays